S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
AI Stock Caught Trading Under Secret Name (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
AI Stock Caught Trading Under Secret Name (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Better Than Oil Stocks (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
AI Stock Caught Trading Under Secret Name (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
AI Stock Caught Trading Under Secret Name (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Better Than Oil Stocks (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
AI Stock Caught Trading Under Secret Name (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
AI Stock Caught Trading Under Secret Name (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Better Than Oil Stocks (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
AI Stock Caught Trading Under Secret Name (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
AI Stock Caught Trading Under Secret Name (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Better Than Oil Stocks (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover

Salarius Pharmaceuticals (SLRX) Competitors

$0.58
+0.02 (+3.59%)
(As of 02/23/2024 ET)

SLRX vs. ALLR, CNSP, ENSC, MDVL, CING, NMTR, ZVSA, PTEIQ, JAGX, and MNPR

Should you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include Allarity Therapeutics (ALLR), CNS Pharmaceuticals (CNSP), Ensysce Biosciences (ENSC), MedAvail (MDVL), Cingulate (CING), 9 Meters Biopharma (NMTR), ZyVersa Therapeutics (ZVSA), PolarityTE (PTEIQ), Jaguar Health (JAGX), and Monopar Therapeutics (MNPR). These companies are all part of the "medical" sector.

Salarius Pharmaceuticals vs.

Allarity Therapeutics (NASDAQ:ALLR) and Salarius Pharmaceuticals (NASDAQ:SLRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, community ranking and media sentiment.

In the previous week, Salarius Pharmaceuticals had 1 more articles in the media than Allarity Therapeutics. MarketBeat recorded 3 mentions for Salarius Pharmaceuticals and 2 mentions for Allarity Therapeutics. Salarius Pharmaceuticals' average media sentiment score of 0.46 beat Allarity Therapeutics' score of 0.12 indicating that Allarity Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Allarity Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Salarius Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Allarity Therapeutics has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500. Comparatively, Salarius Pharmaceuticals has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500.

10.7% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 5.9% of Salarius Pharmaceuticals shares are owned by institutional investors. 0.1% of Allarity Therapeutics shares are owned by company insiders. Comparatively, 5.5% of Salarius Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Salarius Pharmaceuticals received 25 more outperform votes than Allarity Therapeutics when rated by MarketBeat users. Likewise, 54.17% of users gave Salarius Pharmaceuticals an outperform vote while only 50.00% of users gave Allarity Therapeutics an outperform vote.

CompanyUnderperformOutperform
Allarity TherapeuticsOutperform Votes
1
50.00%
Underperform Votes
1
50.00%
Salarius PharmaceuticalsOutperform Votes
26
54.17%
Underperform Votes
22
45.83%

Allarity Therapeutics has higher earnings, but lower revenue than Salarius Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allarity TherapeuticsN/AN/A-$19.48MN/AN/A
Salarius Pharmaceuticals$1.84M1.24-$31.61M-$7.14-0.08

Salarius Pharmaceuticals' return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Allarity TherapeuticsN/A N/A -95.59%
Salarius Pharmaceuticals N/A -236.94%-159.70%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allarity Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Salarius Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Salarius Pharmaceuticals beats Allarity Therapeutics on 6 of the 11 factors compared between the two stocks.


Get Salarius Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SLRX vs. The Competition

MetricSalarius PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.27M$6.70B$5.19B$7.50B
Dividend YieldN/A2.66%2.85%3.86%
P/E Ratio-0.0817.75243.4118.56
Price / Sales1.241,204.743,354.09207.18
Price / CashN/A16.5299.7955.40
Price / Book0.134.554.404.60
Net Income-$31.61M$149.04M$115.30M$207.21M
7 Day Performance-0.47%1.07%0.88%-1.09%
1 Month Performance10.73%9.45%7.02%3.27%
1 Year Performance-73.41%4.11%10.09%5.59%

Salarius Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALLR
Allarity Therapeutics
0 of 5 stars
$0.41
-2.4%
N/A-99.9%$1.95MN/A0.0014News Coverage
Positive News
CNSP
CNS Pharmaceuticals
0 of 5 stars
$0.28
-6.6%
N/A-83.8%$1.76MN/A0.003Gap Down
ENSC
Ensysce Biosciences
2.4073 of 5 stars
$0.86
-24.6%
$11.00
+1,179.1%
-85.5%$2.71M$2.52M-0.047Gap Down
MDVL
MedAvail
0 of 5 stars
N/AN/AN/A$2.90M$43.11M0.00279Gap Down
CING
Cingulate
2.2805 of 5 stars
$1.17
+4.5%
$8.00
+583.8%
-96.7%$1.10MN/A-0.0415News Coverage
Gap Down
NMTR
9 Meters Biopharma
0 of 5 stars
N/A$1.70
+∞
N/A$1.04MN/A-0.0210
ZVSA
ZyVersa Therapeutics
2.5971 of 5 stars
$0.56
-6.7%
$87.50
+15,665.8%
-98.9%$688,000.00N/A0.007News Coverage
Gap Down
PTEIQ
PolarityTE
0 of 5 stars
$0.10
flat
N/AN/A$615,000.00$810,000.00-0.0342
JAGX
Jaguar Health
0 of 5 stars
$0.08
-10.9%
N/A-97.2%$4.16M$11.96M0.0060
MNPR
Monopar Therapeutics
2.6292 of 5 stars
$0.33
flat
$13.00
+3,838.2%
-60.7%$4.91MN/A-0.4611News Coverage
Gap Up

Related Companies and Tools

This page (NASDAQ:SLRX) was last updated on 2/25/2024 by MarketBeat.com Staff